Price (delayed)
$3.22
Market cap
$103.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$102.63M
Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type
There are no recent dividends present for ANIX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.